699500 | Kdo2-Lipid A (KLA)

Di[3-deoxy-D-manno-octulosonyl]-lipid A (ammonium salt)


Powder

Size SKU Packaging Price
1mg 699500P-1mg 699500P-1mg $184.00
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
Please select an option above.
${sku} - ${concentration}

Kdo2-Lipid A (KLA)

Kdo2-Lipid A (KLA)

Di[3-deoxy-D-manno-octulosonyl]-lipid A (ammonium salt)

A new preparation of the saccharolipid glycan, Kdo2-Lipid A (KLA), is a nearly homogeneous Re lipopolysaccharide (LPS) substructure with endotoxin activity equal to that of native LPS. KLA is comparable to LPS and its activity is reduced by >103 in cells from TLR-4 deficient mice. The advantage of KLA over LPS is that it is a reproducible, defined natural product, and it can be detected by ESI/MS at the low concentrations used to stimulate animal cells. The purity of KLA should also facilitate the structural analysis of its complexes with signaling receptors, such as TLR-4/MD2.

New research* shows 1μg KLA induces

the same response as 10μg LPS.

Perform experiments at half the cost of using LPS!

 
* Saito, O., C.I. Svensson, M.W. Buczynski, K. Wegner, X.Y. Hua, S. Codeluppi, R.H. Schaloske, R.A. Deems, E.A. Dennis, and T.L. Yaksh. (2010). Spinal glial TLR4-mediated nociception and production of prostaglandin E and TNF. Br J Pharmacol 160:1754-64.
For a list of cell and solution protocols utilizing KLA, please see information on the LIPID MAPS website at the following link.
Hygroscopic
No
Light Sensitive
No
Purity
>95%
Stability
1 Year
Storage Temperature
-20°C
CAS Number
1246298-62-3
CAS Registry Number is a Registered Trademark of the American Chemical Society
Molecular Weight
2306.840
Exact Mass
0.000
Synonyms
<p>KLA</p>
Chung, H.S. and C.R. Raetz. (2010). Interchangeable domains in the Kdo transferases of Escherichia coli and Haemophilus influenzae. Biochemistry 49:4126-37. [Abstract]   Andreyev, A.Y., Fahy, E., Guan, Z., Kelly, S., Li, X., McDonald, J.G., Milne, S., Myers, D., Park, H., Ryan, A., Thompson, B.M., Wang, E., Zhao, Y., Brown, H.A., Merrill, A.H., Raetz, C.R., Russell, D.W., Subramaniam, S., Dennis, E.A. (2010) Subcellular organelle lipidomics in TLR-4-activated macrophages. J Lipid Res. 51:2785-97. [PubMed] Saito, O., Svensson, C.I., Buczynski, M.W., Wegner, K., Hua, X.-Y., Codeluppi, S., Schaloske, R.H., Deems, R.A., Dennis, E.A., Yaksh, T.L. (2010) Spinal glial TLR4-mediated nociception and production of prostaglandin E2 and TNF. British Journal of Pharmacology 160:1754–1764. [Abstract] Sasaki, H., White, S.H. (2008)Aggregation behavior of an ultra-pure lipopolysaccharide that stimulates TLR-4 receptors. Biophys J. 95:986-93. [PubMed] Wei, J., Wang, E., Kelly, S.,Sullards, C.,Merrill, A. (2007)Up-regulation of de novo sphingolipid biosynthesis through serine palmitoyltransferease in RAW 264.7 cells upon Kdo2-Lipid A treatment. FASEB J. 21:487.11 [Abstract] Allegood, J.,Wang, E.,Sullards, M.C.,Merrill, A.H., Jr. (2007)Quantitative analysis of sulfatides in RAW 264.7 cells treated with Kdo2-Lipid A. FASEB J. 21:779.12 [Abstract] Raetz, C.R., Garrett, T.A., Reynolds, C.M., Shaw, W.A., Moore, J.D., Smith, D.C., Jr, Ribeiro, A.A., Murphy, R.C., Ulevitch, R.J., Fearns, C., Reichart, D., Glass, C.K., Benner, C., Subramaniam, S., Harkewicz, R., Bowers-Gentry, R.C., Buczynski, M.W., Cooper, J.A., Deems, R.A., Dennis, E.A. (2006) Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J Lipid Res. 47:1097-111. [PubMed]
Packaging for animal studies available. Please contact technical@avantilipids.com.
References:
Gu, B.B., J.F. Miao, Y.M. Zhu, Y.E. Deng, and S.X. Zou. (2009). Protective effect of retinoid against endotoxin-induced mastitis in rats. Inflamm Res 58:81-8. Yajima, S., H. Morisaki, R. Serita, T. Suzuki, N. Katori, T. Asahara, K. Nomoto, F. Kobayashi, A. Ishizaka, and J. Takeda. (2009). Tumor necrosis factor-alpha mediates hyperglycemia-augmented gut barrier dysfunction in endotoxemia. Crit Care Med 37:1024-30. Nacira, S., F. Meziani, O. Dessebe, V. Cattan, S. Collin, C. Montemont, S. Gibot, P. Asfar, A. Ramaroson, V. Regnault, M. Slama, T. Lecompte, P. Lacolley, and B. Levy. (2009). Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med 37:246-55.